[Skip to Content]
[Skip to Content Landing]
Views 2,287
Citations 0
Biotech Innovations
July 10, 2018

Immunotherapy Leads to Complete Regression in Late-Stage Breast Cancer

JAMA. 2018;320(2):127. doi:10.1001/jama.2018.9486

National Cancer Institute (NCI) researchers recently reported complete and durable regression of chemorefractory metastatic ERBB2-negative and ER-positive breast cancer in a woman who received an experimental immunotherapy. The case report, published recently in Nature Medicine, involved a 49-year-old patient whose late-stage cancer was progressing despite multiple lines of chemotherapy and hormone treatments.